Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation

Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation

Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), but its clinical effects are still limited. In this study we identify Quiescin sulfhydryl oxidase 1 (QSOX1) acting as a cellular pro-oxidant, specifically in the context of sorafenib treatment of HCC. QSOX1...

Full description

Bibliographic Details
Main Authors: Jialei Sun, Chenhao Zhou, Yue Zhao, Xiaofei Zhang, Wanyong Chen, Qiang Zhou, Bo Hu, Dongmei Gao, Lisa Raatz, Zhefang Wang, Peter J. Nelson, Yuchao Jiang, Ning Ren, Christiane J. Bruns, Haijun Zhou
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:Redox Biology
Subjects:
QSOX1
HCC
ROS
Antioxidant
Ferroptosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2213231721000902

Internet

http://www.sciencedirect.com/science/article/pii/S2213231721000902

Similar Items